Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

RSS icon

CRT: When to stop dual-antiplatelet therapy after DES? We dont know!

WASHINGTON, D.C.--"We dont know when it is safe to stop dual-antiplatelet therapy after drug-eluting stent (DES) implantation," said Laura Mauri, MD, of Brigham and Womens Hospital in Boston, during a Feb. 6 presentation at the Cardiovascular Research Technologies (CRT) meeting.

AHJ: PCI patients may be better off at specialty hospitals

Patients who undergo PCI at specialty hospitals may fare better than those at other types of hospitals, a study published in the February issue of the American Heart Journal found, further fueling the debate whether certain types of hospitals deliver better patient care.

CRT: Give prasugrel or ticagrelor a chance for ACS patients

WASHINGTON, D.C.--While the decision about which antiplatelet drug to use for PCI may vary, Stephen D. Wiviott, MD, of Brigham and Womens Medical Center in Boston, suggested that the third-generation options of prasugrel (Effient, Eli Lilly/Daiichi Sankyo) or ticagrelor (Brilinta, AstraZeneca) may be the best options for patients with acute coronary syndromes (ACS). He made this case during a Feb. 5 presentation at the annual Cardiovascular Research Technologies (CRT) meeting.

JACC: Left main PCI use low, linked to adverse events

Less than 5 percent of patients with unprotected left main coronary artery (ULMCA) stenosis received ULMCA PCI. Researchers found that the PCI is usually carried out in higher risk patients, and the elderly tend to see more adverse events, according to reports from the 2004-2008 National Cardiovascular Data Registry published in the Feb. 14 issue of the Journal of the American College of Cardiology.

CABG Grafts: The Debate Beats On

Experts hash out the most updated data on endovascular vein harvesting and radial artery grafting, and which surgical strategies produce the best patient outcomes.

Feature: More transplant volume may pump up outcomes

Each year more than 2,000 heart transplants are performed in the U.S. For patients with end-stage heart failure (HF) whose heart cannot pump blood sufficiently, when medical therapies fail, heart transplantation may be the last resort to restore quality of life. Yet, previously published data have shown that many transplant centers performed at volumes and survival rates that are less than optimal.

Cell therapy expert Doris Taylor moves to Texas Heart

Doris Taylor, PhD, a leading cell therapy and cardiac regeneration scientist, will join the Texas Heart Institute in Houston, beginning March 1.

CRT: Can PHOENIX raise cangrelor from the ashes?

WASHINGTON, D.C.Based on the current clinical data that has emerged on cangrelor (The Medicines Company)which Steven R. Steinhubl, MD, defined as relatively non-compelling during a presentation Feb. 5 at the Cardiovascular Research Technologies (CRT) meetingthe PHOENIX trial results may be the agents only hope for approval.

Displaying 2089 - 2096 of 2712

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.